4th Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$1,290,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Inter Partes Review (IPR) process. Patent Settlements. S.1390: STRONGER Patents Act of 2017. S.1948: A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents.

Contacted: HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC)

Bills named: S. 1390 (115th), S. 1948 (115th)

Medicare/Medicaid MMM

Medicare Part D Program and Generic Drugs. Medicare reimbursement for biosimilars. Medicaid Rebate Penalty. Medicare Part D Low Income Subsidy (LIS) Program.

Contacted: Food & Drug Administration (FDA); Federal Trade Commission (FTC); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Budget/Appropriations BUD

FDA Funding. H.R.5054/S.2956: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. H.R.3354: Department of the Interior, Environment, and Related Agencies Appropriations Act, 2018.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
CHRISTIAN OMAR CRUZ —
ERIK C KOMENDANT —
KRISTIN MURPHY —

Contacted: Federal Trade Commission (FTC); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE

Bills named: H.R. 5054 (115th), S. 2956 (115th), H.R. 3354 (115th)

Pharmacy PHA

Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendments (GDUFA). Biosimilar User Fee Act (BsUFA). Labeling of Generic Drugs. Biosimilars Naming. Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products. Prescription Drug Costs. H.R.2051: FAST Generics Act of 2017. S.124: Preserve Access to Affordable Generics Act. H.R.1245/S.469: Affordable and Safe Prescription Drug Importation Act. H.R.1314: Bipartisan Budget Act of 2015. Risk Evaluation and Mitigation Strategies (REMS). Biologic Exclusivity. Biologics Price Competition and Innovation Act (BPCIA). H.R.2562/S.1115: Making Pharmaceutical Markets More Competitive Act. S.771: Improving Access To Affordable Prescription Drugs Act. Pharmaceutical Exclusivity. H.R.2212/S.974: CREATES Act of 2017. H.R.2439/S.1131: Fair Accountability and Innovative Research Drug Pricing Act of 2017. S.297: Increasing Competition in Pharmaceuticals Act. H.R.749: Lower Drug Costs through Competition Act. H.R.2430/S.934: FDA Reauthorization Act of 2017. H.R.1223/S.1509: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017.

Contacted: SENATE; Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC)

Bills named: H.R. 2212 (115th), S. 974 (115th), H.R. 749 (115th), H.R. 2051 (115th), H.R. 2430 (115th), H.R. 1223 (115th), H.R. 1314 (115th), H.R. 2439 (115th), S. 1509 (115th), S. 1131 (115th), H.R. 2562 (115th), S. 934 (115th), S. 469 (115th), S. 124 (115th), H.R. 1245 (115th), S. 297 (115th), S. 771 (115th), S. 1115 (115th)

Trade (domestic/foreign) TRD

General Trade Issues. Trans-Pacific Partnership (TPP). Transatlantic Trade and Investment Partnership (TTIP). Biologic Exclusivity. North American Free Trade Agreement.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
CHRISTIAN OMAR CRUZ —
JEFFREY FRANCER —
DAVID R. GAUGH —
ERIK C KOMENDANT —
KRISTIN MURPHY —

Contacted: Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); SENATE; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC)

Taxation/Internal Revenue Code TAX

Taxation Issues Related to Opioid Pharmaceuticals. User Fee Programs.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
MICHAEL BRZICA —
CHRISTIAN OMAR CRUZ —
DAVID R. GAUGH —
ERIK C KOMENDANT —
KRISTIN MURPHY —

Contacted: U.S. Trade Representative (USTR); Federal Trade Commission (FTC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.